Sungho Bea/LinkedIn
Aug 2, 2025, 17:34
Oral Anticoagulation in VTE: Apixaban Safer and More Effective than Rivaroxaban or Warfarin
The Heart has published on X:
“Oral Anticoagulation and Risk of Adverse Clinical Outcomes in Venous Thromboembolism
Apixaban was asso with a lower risk of recurrent VTE and major bleeding compared to rivaroxaban and warfarin in pts initiating oral anticoagulant therapy.”
Title: Oral Anticoagulation and Risk of Adverse Clinical Outcomes in Venous Thromboembolism
Authors: Sungho Bea, PharmD, PhD; Geetha S. Iyer, PhD; Dae Hyun Kim, MD, MPH, ScD; Kueiyu Joshua Lin, MD, ScD, MPH; Yichi Zhang, MS; Heidi Zakoul, BS; Helen Tesfaye, PharmD, MSc; Katsiaryna Bykov, PharmD, ScD
Read the full article here.
Latest scientific advancements in hematology featured in Hemostasis Today.
-
Feb 1, 2026, 13:32Shiny K. Kajal: A Series On Reaching the Diagnosis of Immune Thrombocytopenia
-
Feb 1, 2026, 13:26Mary Cushman: Association of Atrial Fibrillation with Risk of Incident Cognitive Impairment
-
Feb 1, 2026, 13:23Abdulrahman Katib: Extended Low-Dose DOAC May Reduce VTE Recurrence
-
Feb 1, 2026, 13:22Jeff June: The Stroke That Wasn’t New – Why ‘Cryptogenic’ Often Means Undetected
-
Feb 1, 2026, 13:11Panagiotis Doukas: Plasma Desmosine as a Biomarker of Increased Proteolytic Activity in the Aortic Wall
-
Feb 1, 2026, 12:54Pierpaolo Di Micco: Starting a New Era for Anticoagulant Treatments
-
Feb 1, 2026, 12:16Erwin Loh: Immunotherapy Reduces Plaque in Arteries of Mice
-
Feb 1, 2026, 12:06Ney Carter Borges: The Central Role of Endothelial Dysfunction in Cardiovascular Disease Progression
-
Feb 1, 2026, 12:05Causes of Anemia – A Quick Overview From Mahnoor Shah